NCT04645498

COVID-19 and Hereditary Metabolic Diseases

Prospective Study on the Impact of COVID-19 on the Equilibrium of Hereditary Metabolic Disease (MHM) in Patients With or Who Have Contracted COVID-19

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 77 (estimated)
• Sponsor: University Hospital, Lille · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

No additional risk factors have been identified in patients with Inherited Metabolic Diseases (IMD) for contracting or presenting complications of COVID-19 compared to the general population. Yet, IMD patients have cell/tissue alterations that could constitute a potential direct or indirect target for the virus. We do not know the impact of this infection on patients suffering from MHM, nor the possible effect of specific treatment of MHM on the evolution of COVID-19. This study will collect French IMD patients having or having had COVID-19 infection. The main objective is to estimate among IMD patients contracting COVID-19 the frequency of disease aggravation or metabolic decompensation. The secondary objectives will be : a. to evaluate the incidence of COVID-19 diagnosed in a given group of IMD when the number of patients with this IMD is known (Urea Cycle Deficiency, Gaucher Disease). b. to evaluate the impact of IMD on the and severity of COVID-19 infection

Conditions

• Covid19
• Metabolism, Inborn Errors

Timeline

• Start date: 2021-02-01
• Primary completion: 2023-02-01
• Completion: 2023-02-01
• First posted: 2020-11-27
• Last updated: 2022-03-02

Locations

1 site across 1 country: France